ADA and hepatocellular carcinoma: Similarly, Chan and his colleagues, analyzing hepatocellular carcinoma patients treated with Atezolizumab, found that 17.4% of patients exhibited elevated ADA levels and concluded that these high levels may reduce the exposure to Atezolizumab and consequently weaken its anticancer effect [38].